Recruitment Status

Not yet recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3253

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Uncomplicated Urinary Tract Infections
Interventions: Pivya (Pivmecillinam 185 mg), Nitrofurantoin 100 mg (nitrofurantoin monohydrate/macrocrystalline capsule); Drug
Lead sponsor: Alembic Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dearborn Heights, Michigan

Conditions: Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor, Recurrent Gastrointestinal Stromal Tumor, Refractory Malignant Gastrointestinal Stromal Tumor, Unresectable Malignant Gastrointestinal Stromal Tumor
Interventions: Aldesleukin, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography Test, Filgrastim, Fludarabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Surgical Procedure, Tumor Infiltrating Lymphocyte Therapy; Biological · Procedure · Drug
Lead sponsor: Joal Beane; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), MS, MS (Multiple Sclerosis), Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Autoimmune
Interventions: C-CAR168; Drug
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Gilbert, Arizona • La Jolla, California

Conditions: ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Clear Cell Renal Cell Cancer (ccRCC)
Interventions: 177Lu-TLX250; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Duarte, California • San Diego, California • Miami, Florida + 5 more

Conditions: Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement
Interventions: C-CAR168; Biological
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
Interventions: Maintenance Therapy, No intervention; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Influenza, COVID-19, Vaccination Willingness
Interventions: Survey; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Hiv
Interventions: Workforce Development (WD) strategies, Quality Management (QM) and Mystery Shopper (MS) Feedback; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: HIV, Gonorrhea, Chlamydia, Anal Cancer Squamous Cell
Interventions: PEACHES 2.0 Implementation Strategies; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: Biloxi, Mississippi

Conditions: Dementia, Alzheimer's Disease and Related Dementias
Interventions: HomeCare; Device
Lead sponsor: HiDO Technologies; Industry
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Davis, California

Conditions: Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD), Lewy Body Disease
Interventions: Not listed
Lead sponsor: BioSensics; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 2
States / cities: Lutherville, Maryland • Boston, Massachusetts

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Not yet recruiting clinical trials

Filter and sort this status page

Live official records

A Study to Investigate Pivmecillinam Versus Nitrofurantoin in Female Adolescents 12 to Less Than 18 Years of Age With Uncomplicated Urinary Tract Infection

Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy

Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

Flu COVID Vaccine Views

Scaling Up Implementation Strategies to Improve the DIAGNOSE and PREVENT Pillars for Young MSM in Florida

Improving Clinic Delivery of HIV-related Anal Health Services

HomeCare Medication Management for People With Dementia

Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)